Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Knowing what to look for and how to manage the changes can make a difference. Secondary progressive MS (SPMS) can affect both physical health and cognitive abilities. Results from a small 2025 ...

Enrollment is now complete in two Phase 3 clinical trials testing vidofludimus calcium in adults with relapsing forms of ...

MS is marked by chronic inflammation and demyelination in the central nervous system. Demyelination is the process in which ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Location : Boston Convention & Exhibition Center, Boston, MA ...

A new study reveals that mitochondrial dysfunction plays a central role in the loss of Purkinje neurons in the cerebellum, ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...